Major prize for transforming rheumatoid arthritis treatment

26 March 2014

Sir Marc Feldmann and Sir Ravinder Maini of the Kennedy Institute of Rheumatology have been named 2014 Canada Gairdner Award winners, one of the world's most prestigious awards for medical research.

Their discovery of an antibody-based treatment, or 'anti-TNF' therapy, for the treatment of rheumatoid arthritis and other inflammatory diseases has transformed the lives of many patients.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

19 January 2021

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

MRC HIU appoints new Director

6 January 2021

We are pleased to announce that Professor Alison Simmons has been appointed as the new Director of the MRC Human Immunology Unit.

New Year's Honours 2021

1 January 2021

Members of the Medical Sciences Division have been recognised in the New Year's Honours list for 2021.

Oxford University awarded £2.4 million to fund DPhil research in inflammation, immunology and musculoskeletal disease

18 December 2020

Oxford University has been awarded a £2.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.

Professor Sir Rory Collins awarded the MRC Millennium Medal 2020

17 December 2020

Professor Sir Rory Collins, Head of the Nuffield Department of Population Health, and Principal Investigator and Chief Executive of UK Biobank, has been awarded the Medical Research Council (MRC) Millennium Medal 2020, the MRC’s most prestigious personal award.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

9 December 2020

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.